Logo

Qiagen AdnaTest ProstateCancerPanel AR-V7 and LungCancer Kits

Apr 12, 2018

Qiagen this week launched the AdnaTest ProstateCancerPanel AR-V7 and AdnaTest LungCancer kits at the American Association for Cancer Research annual meeting.

AdnaTest ProstateCancerPanel AR-V7 detects the androgen receptor splice variant 7 in circulating tumor cells (CTCs) of prostate tumor origin isolated from blood samples to investigate potential resistance to drugs for advanced prostate cancer. With an exclusive worldwide license from Johns Hopkins University for nucleic acid detection of the AR-V7 biomarker for diagnostic use, Qiagen is now launching the test for research use.

AdnaTest LungCancer provides insights into the molecular mechanisms of lung cancer through highly specific selection of CTCs, including stem cell-like cells implicated in cancer growth and epithelial-mesenchymal transition, an important marker of cancer therapy resistance. A proprietary set of antibodies provides sensitive detection of lung cancer-associated targets through reverse-transcriptase PCR, and the open system enables users to add targets of interest.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.